Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 8i Enterprises Acquisition Corp.JFK · Entity 156021 | Director | March 27, 2019 | March 27, 2019 |
| Protagenic Therapeutics, Inc.\newPTIX · Entity 8496 | Chief Financial Officer | March 25, 2024 | March 30, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
8i Enterprises Acquisition Corp.
Report date March 27, 2019 · Filed March 27, 2019
This filing explicitly reported no securities owned.
Protagenic Therapeutics, Inc.\new
Report date March 25, 2024 · Filed March 30, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PTIX Common stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2034-03-25 | Direct | 100,000 |
Reported balance
After 2024-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-25 · Grant · Acquired 100,000 · Balance 100,000 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EUDA Health Holdings Ltd
Report date November 17, 2022 · Filed November 25, 2022
Section 16 reporting ended · disclosed 2022-11-25. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2024 Filed Mar 30, 2024 01:29 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantPTIX Common stock Options · Derivative | 100,000 | $1.74 Strike: $1.74 | $174,000.00 |
DisclosureSEC source: 0001493152-24-012069 · ownership.xml · derivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: PTIX Common Stock, Par Value $0.0001 · 100,000 shares Expires 2034-03-25 Read SEC document |
| October 12, 2023 Filed Oct 13, 2023 16:48 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | PurchasePTIX Common Stock | 8,000 | $0.81 | $6,480.00 |
DisclosureSEC source: 0001493152-23-037136 · ownership.xml · nonDerivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,815 Read SEC document |
| May 18, 2022 Filed May 18, 2022 21:11 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | PurchasePTIX Common Stock | 8,000 | $0.72 | $5,760.00 |
DisclosureSEC source: 0001493152-22-014338 · ownership.xml · nonDerivative · entry 2 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,260 Read SEC document |
| May 17, 2022 Filed May 18, 2022 21:11 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | PurchasePTIX Common Stock | 23,000 | $0.71 | $16,330.00 |
DisclosureSEC source: 0001493152-22-014338 · ownership.xml · nonDerivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,260 Read SEC document |
| June 03, 2021 Filed Jun 3, 2021 22:13 UTC | Protagenic Therapeutics, Inc.\new PTIXW · Entity 8496 | PurchasePTIXW Common Stock 5-year warrants strike price $4.98 · Derivative | 16,900 | $0.38 Strike: $4.98 | $6,422.00 |
DisclosureSEC source: 0001493152-21-013554 · ownership.xml · derivative · entry 2 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: PTIX Common Stock · 16,900 shares Expires 2026-04-26 Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 22:13 UTC | Protagenic Therapeutics, Inc.\new PTIXW · Entity 8496 | PurchasePTIXW Common Stock 5-year warrants strike price $4.98 · Derivative | 100 | $0.38 Strike: $4.98 | $38.00 |
DisclosureSEC source: 0001493152-21-013554 · ownership.xml · derivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,100 Underlying: PTIX Common Stock · 100 shares Expires 2026-04-26 Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 10:05 UTC | Protagenic Therapeutics, Inc.\new PTIXW · Entity 8496 | PurchasePTIXW Common Stock 5-year warrants strike price $4.98 · Derivative | 3,000 | $0.38 Strike: $4.98 | $1,140.00 |
DisclosureSEC source: 0001493152-21-013279 · ownership.xml · derivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: PTIX Common Stock · 3,000 shares Expires 2026-04-26 Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:24 UTC | Protagenic Therapeutics, Inc.\new PTIXW · Entity 8496 | PurchasePTIXW Common Stock 5-year warrants strike price $4.98 · Derivative | 18,000 | $0.31 Strike: $4.98 | $5,580.00 |
DisclosureSEC source: 0001493152-21-012357 · ownership.xml · derivative · entry 2 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: PTIX Common Stock · 18,000 shares Expires 2026-04-26 Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:24 UTC | Protagenic Therapeutics, Inc.\new PTIXW · Entity 8496 | PurchasePTIXW Common Stock 5-year warrants strike price $4.98 · Derivative | 12,000 | $0.32 Strike: $4.98 | $3,840.00 |
DisclosureSEC source: 0001493152-21-012357 · ownership.xml · derivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: PTIX Common Stock · 12,000 shares Expires 2026-04-26 Read SEC document |
| April 30, 2021 Filed May 3, 2021 20:15 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | PurchasePTIX Common Stock | 1,000 | $2.29 | $2,290.00 |
DisclosureSEC source: 0001493152-21-010335 · ownership.xml · nonDerivative · entry 2 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,260 Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:15 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | PurchasePTIX Common Stock | 1,000 | $2.29 | $2,290.00 |
DisclosureSEC source: 0001493152-21-010335 · ownership.xml · nonDerivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,260 Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 21:05 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantPTIX Common stock Options · Derivative | 124,998 | $1.75 Strike: $1.75 | $218,746.50 |
DisclosureSEC source: 0001493152-20-013712 · ownership.xml · derivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,998 Underlying: PTIX Common Stock, Par Value $0.0001 · 124,998 shares Expires 2030-07-18 Read SEC document |
| February 21, 2020 Filed Feb 27, 2020 01:15 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantPTIX Common stock Options · Derivative | 307,497 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001493152-20-003033 · ownership.xml · derivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,497 Underlying: PTIX Common Stock, Par Value $0.0001 · 307,497 shares Expires 2030-02-21 F1 · price: As this was an option grant, there was no cost to the recipient. Read SEC document |
| March 20, 2019 Filed Mar 25, 2019 10:10 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantPTIX Common stock Options · Derivative | 41,667 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001493152-19-003805 · ownership.xml · derivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,667 Underlying: PTIX · 41,667 shares Expires 2029-03-20 Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 18:46 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001437749-17-017238 · rdgdoc.xml · derivative · entry 1 Arrow Alexander K. · CIK 0001497166 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Protagenic Therapeutics, Inc. Common Stock · 75,000 shares Expires 2027-10-16 F1 · derivative.exercise_date: Vesting in equal installments over 36 months, full vesting upon change of control Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.